224 related articles for article (PubMed ID: 7843255)
1. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis.
Ozmen L; Roman D; Fountoulakis M; Schmid G; Ryffel B; Garotta G
Eur J Immunol; 1995 Jan; 25(1):6-12. PubMed ID: 7843255
[TBL] [Abstract][Full Text] [Related]
2. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
3. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice.
Haas C; Ryffel B; Le Hir M
J Immunol; 1998 Apr; 160(8):3713-8. PubMed ID: 9558072
[TBL] [Abstract][Full Text] [Related]
4. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis.
Enghard P; Langnickel D; Riemekasten G
Scand J Rheumatol; 2006; 35(3):209-16. PubMed ID: 16766368
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
[TBL] [Abstract][Full Text] [Related]
6. Sophorae radix reduces autoimmune response in NZB/w F1 systemic lupus erythematosus mouse model.
Ko E; Lee Y; Park N; Cho C; Yim YN; Kim J; Kim YS; Kim D; Shin MK; Hong MC; Bae H
Lupus; 2007; 16(5):335-41. PubMed ID: 17576735
[TBL] [Abstract][Full Text] [Related]
7. Anti-T cell receptor antibody treatment of mice with lupus-like graft versus host disease: suppression of glomerulonephritis without reduction in anti-DNA antibody levels.
Maeda T; Nomoto K
J Rheumatol; 1995 Dec; 22(12):2259-65. PubMed ID: 8835559
[TBL] [Abstract][Full Text] [Related]
8. Toxoplasma gondii infection inhibits the development of lupus-like syndrome in autoimmune (New Zealand Black x New Zealand White) F1 mice.
Chen M; Aosai F; Norose K; Mun HS; Ishikura H; Hirose S; Piao LX; Fang H; Yano A
Int Immunol; 2004 Jul; 16(7):937-46. PubMed ID: 15148287
[TBL] [Abstract][Full Text] [Related]
9. Treatment of lupus in NZB/W F1 mice with monoclonal antibody against Fas ligand.
Nakajima A; Hirai H; Kayagaki N; Yoshino S; Hirose S; Yagita H; Okumura K
J Autoimmun; 2000 Mar; 14(2):151-7. PubMed ID: 10677246
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of behavioral abnormalities in autoimmune mice by chronic soluble interferon-gamma receptor treatment.
Schrott LM; Crnic LS
Brain Behav Immun; 1998 Jun; 12(2):90-106. PubMed ID: 9646935
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.
Liang B; Gardner DB; Griswold DE; Bugelski PJ; Song XY
Immunology; 2006 Nov; 119(3):296-305. PubMed ID: 17067309
[TBL] [Abstract][Full Text] [Related]
12. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule.
Nakajima A; Azuma M; Kodera S; Nuriya S; Terashi A; Abe M; Hirose S; Shirai T; Yagita H; Okumura K
Eur J Immunol; 1995 Nov; 25(11):3060-9. PubMed ID: 7489744
[TBL] [Abstract][Full Text] [Related]
13. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4.
Wofsy D; Seaman WE
J Immunol; 1987 May; 138(10):3247-53. PubMed ID: 3106478
[TBL] [Abstract][Full Text] [Related]
14. Lipopolysaccharide-induced glomerulonephritis develops in the absence of interferon-gamma signaling.
Haas C; Car B; Ryffel B; Le Hir M
Exp Nephrol; 1996; 4(4):222-30. PubMed ID: 8864725
[TBL] [Abstract][Full Text] [Related]
15. Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody.
Ravirajan CT; Wang Y; Matis LA; Papadaki L; Griffiths MH; Latchman DS; Isenberg DA
Rheumatology (Oxford); 2004 Apr; 43(4):442-7. PubMed ID: 15024133
[TBL] [Abstract][Full Text] [Related]
16. Defects in the regulation of anti-DNA antibody production in aged lupus-prone (NZB x NZW)F1 mice: analysis of T-cell lymphokine synthesis.
Sato MN; Minoprio P; Avrameas S; Ternynck T
Immunology; 1995 May; 85(1):26-32. PubMed ID: 7635519
[TBL] [Abstract][Full Text] [Related]
17. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice.
Haas C; Ryffel B; Le Hir M
J Immunol; 1997 Jun; 158(11):5484-91. PubMed ID: 9164971
[TBL] [Abstract][Full Text] [Related]
18. Treatment with anti-interferon-gamma monoclonal antibodies modifies experimental autoimmune encephalomyelitis in interferon-gamma receptor knockout mice.
Espejo C; Penkowa M; Sáez-Torres I; Xaus J; Celada A; Montalban X; Martínez-Cáceres EM
Exp Neurol; 2001 Dec; 172(2):460-8. PubMed ID: 11716570
[TBL] [Abstract][Full Text] [Related]
19. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice.
Schwarting A; Wada T; Kinoshita K; Tesch G; Kelley VR
J Immunol; 1998 Jul; 161(1):494-503. PubMed ID: 9647261
[TBL] [Abstract][Full Text] [Related]
20. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.
Schwarting A; Paul K; Tschirner S; Menke J; Hansen T; Brenner W; Kelley VR; Relle M; Galle PR
J Am Soc Nephrol; 2005 Nov; 16(11):3264-72. PubMed ID: 16221871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
